Eric M Thompson
Washington University School of Medicine · Washington University - St. Louis Children's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric M Thompson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:50 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06639607 · PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaWashington University School of Medicine · suspended · Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma · principal investigator
- Ph2NCT05096481 · PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaNationwide Children's Hospital · recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)R01CA296813 · NCI · WASHINGTON UNIVERSITY · fiscal years 2025 to 2026 · $532,488 awarded in 2026Grant number is on one of their registry trials
- Expanding CMV peptide vaccine with novel combinations and pathologiesR03NS138988 · NINDS · WASHINGTON UNIVERSITY · fiscal years 2024 to 2025 · $77,750 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in medulloblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:50 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.Lancet Child Adolesc Health · 202347 citationsRCR 4.0
- A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.Nat Cancer · 202515 citationsRCR 3.2